Clene (CLNN) Competitors

Clene currently has a consensus price target of $33.25, suggesting a potential upside of 476.26%. Nuvectis Pharma has a consensus price target of $39.00, suggesting a potential upside of 122.22%. Given Clene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Clene is more favorable than Nuvectis Pharma.

In the previous week, Nuvectis Pharma had 9 more articles in the media than Clene. MarketBeat recorded 10 mentions for Nuvectis Pharma and 1 mentions for Clene. Nuvectis Pharma's average media sentiment score of 0.75 beat Clene's score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

23.3% of Clene shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Clene has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Clene has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Clene currently has a consensus price target of $33.25, suggesting a potential upside of 476.26%. Bicycle Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 250.00%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Bicycle Therapeutics.

23.3% of Clene shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bicycle Therapeutics has a net margin of -344.95% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Clene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

Clene has higher earnings, but lower revenue than Bicycle Therapeutics. Clene is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Bicycle Therapeutics had 1 more articles in the media than Clene. MarketBeat recorded 2 mentions for Bicycle Therapeutics and 1 mentions for Clene. Bicycle Therapeutics' average media sentiment score of 0.88 beat Clene's score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Cartesian Therapeutics has a net margin of -8,550.65% compared to Clene's net margin of -25,009.70%.

Clene currently has a consensus price target of $33.25, suggesting a potential upside of 476.26%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 220.24%. Given Clene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Clene is more favorable than Cartesian Therapeutics.

Clene has higher earnings, but lower revenue than Cartesian Therapeutics. Clene is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

23.3% of Clene shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Clene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Clene and Clene both had 1 articles in the media. Clene's average media sentiment score of 0.00 equaled Cartesian Therapeutics'average media sentiment score.

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Clene. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 1 mentions for Clene. Eledon Pharmaceuticals' average media sentiment score of 0.24 beat Clene's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Clene has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

23.3% of Clene shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Clene has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Clene currently has a consensus price target of $33.25, suggesting a potential upside of 476.26%. Eledon Pharmaceuticals has a consensus price target of $9.67, suggesting a potential upside of 145.97%. Given Clene's stronger consensus rating and higher possible upside, research analysts clearly believe Clene is more favorable than Eledon Pharmaceuticals.